Commentary|Videos|February 22, 2025
TiNivo-2 Study Shows Comparable Patient-Reported Outcomes in RCC
Author(s)Katy Beckermann, MD, PhD
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 study.
Kathryn Beckermann, MD, PhD, assistant professor in the Department of Medicine, Division of Hematology and Oncology at Vanderbilt School of Medicine in Nashville, Tennessee, discusses how the patient-reported outcomes for tivozanib (Fotivda) plus nivolumab (Opdivo) from the phase 3 TiNivo-2 study (NCT04987203) compare with tivozanib monotherapy in terms of quality of life for the treatment of patients with locally advanced or metastatic clear cell renal cell carcinoma (RCC) following progression on 1 or 2 systemic therapies, including at least 1 immune checkpoint inhibitor.
Data on patient-reported outcomes were presented at the
She then delves into explaining what the key takeaways for integrating these therapies into clinical practice are for patients with RCC who have previously received an immune checkpoint inhibitor.
Transcription:
0:10 | So, I think for our community oncologists, we now have 2 great trials: CONTACT-03 [NCT04338269] and now TiNivo-2, that both say continuation of [immunotherapy] treatment in the refractory setting has no benefit. I think what this trial additionally showed was that there was no increased toxicity across the arms, which was great to see, and [that] further gave us confidence for the use of tivozanib in patients with refractory kidney cancer now and even you know earlier lines of treatment.
REFERENCE
1. Beckermann K, Choueiri T, Motzer R, et al. Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): results of the phase 3 TiNivo-2 study. J Clin Oncol. 2025;43(suppl 5):459. doi:10.1200/JCO.2025.43.5_suppl.459
Related Content
Advertisement
